89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent Phase 1b/2a data show BIO89-100 demonstrated a favorable safety and tolerability profile and robust reductions in liver fat and key lipid markers when dosed weekly or once every two weeks in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG. 89bio is headquartered in San Francisco with operations in Herzliya, Israel.
Our culture is best described by our values:
• Always putting the patient first
• Operating with the highest integrity and ethical standards at all times
• Being authentic in all our transactions
• Acting as a team – collaborating, respecting and caring for one another
• Being entrepreneurial and passionate in our tasks
• Being scientific and rational in our thought process and decision-making
Our culture is best described by our values:
• Always putting the patient first
• Operating with the highest integrity and ethical standards at all times
• Being authentic in all our transactions
• Acting as a team – collaborating, respecting and caring for one another
• Being entrepreneurial and passionate in our tasks
• Being scientific and rational in our thought process and decision-making
Employees: 11-50
Total raised: $60M
Founded date: 2018
Investors 5
| Date | Name | Website |
| 05.01.2023 | K2 HealthV... | k2healthve... |
| - | RA Capital... | racap.com |
| - | OrbiMed | orbimed.co... |
| - | Longitude ... | longitudec... |
| - | K2 HealthV... | k2hv.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.10.2018 | Series A | $60M | - |
Mentions in press and media 17
| Date | Title | Description |
| 28.01.2025 | 89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants | SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio... |
| 12.11.2024 | 89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants | SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio... |
| 12.03.2024 | 89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis | - |
| 08.03.2024 | 89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | - |
| 08.03.2024 | 89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment o... |
| 05.03.2024 | 89bio to Participate in the Leerink Partners Global Biopharma Conference | - |
| 07.12.2023 | 89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants | - |
| 22.03.2023 | NASH Drug Biotech 89bio Nails Phase 2 Goals; Next Up Is a Pivotal Clinical Trial | Biotech company 89bio has data from a mid-stage study showing its NASH drug candidate led to improvement on two measures of the fatty liver disease, results that position the molecule to advance to Phase 3 testing. 89bio said Wednesday that... |
| 29.06.2022 | 89bio, Inc. Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants | SAN FRANCISCO, June 29, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio... |
| 23.09.2020 | Healthcare VC Firm Longitude Capital Closes $585M Fund | What You Should Know: – Healthcare venture capital firm Longitude Capital announces the close of its $585M Longitude Venture Partners IV, L.P. (“LVP4”) fund to invest in transformative healthcare companies. – LVP4 will invest opportunistica... |
Show more